GS
BLUE

GTS Securities’s bluebird bio BLUE Stock Holding History

GTS Securities’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-706
Closed -$7.34K – 1591
2024
Q3 		$7.34K Sell
706
-2,016
-74% -$33.5K ﹤0.01% 3990
2024
Q2 		$53.6K Sell
2,722
-186
-6% -$3.73K ﹤0.01% 3702
2024
Q1 		$74.4K Sell
2,908
-2,703
-48% -$69.3K ﹤0.01% 3579
2023
Q4 		$155K Buy
5,611
+2,995
+114% +$183K ﹤0.01% 3651
2023
Q3 		$159K Buy
2,616
+538
+26% +$37.8K ﹤0.01% 3489
2023
Q2 		$137K Buy
+2,078
New +$152K ﹤0.01% 1081

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

GTS Securities's BLUE Position: Q4 2024 in Review

GTS Securities sold out of bluebird bio (BLUE) in Q4 2024, closing a stake of 706 shares — an estimated $7.34K sold.

GTS Securities first reported a position in BLUE in Q2 2023 and held it in 6 quarters. The position peaked at $159K in Q3 2023. 83 funds tracked by Wall St. Rank hold BLUE as of Q4 2024.

  • GTS Securities reported no remaining bluebird bio position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 706 bluebird bio shares in Q4 2024, an estimated $7.34K.
  • GTS Securities first reported a position in bluebird bio in Q2 2023 and held it in 6 quarters.
  • GTS Securities's bluebird bio position peaked at $159K in Q3 2023.
  • 83 funds tracked by Wall St. Rank held bluebird bio as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.